Samsung, Biogen Co-Operate Amid Italian Antitrust Investigation Into Biosimilar Lucentis
Byooviz Biosimilar Not Available In Italy After August 2021 MAA; Conduct ‘Anomalous’
Did Samsung Bioepis and Biogen choose early US access for its Lucentis biosimilar in exchange for postponing launch in other global markets? That’s what Italy’s competition authority believes, as it kicked off an investigation into both the biosimilar sponsors and originators Genentech and Novartis.
